Sign In
- Home
- Share Prices
- AQSE Share Prices
- Euronext
- US Share Prices
- Stock Tips
- Share Chat
- FX
- News & RNS
- Media
- Trading Brokers
- Finance Tools
- Members
Latest Share Chat
Astrazeneca Share News (AZN)
AZN Share
Price
AZN Share
News
AZN Share
Chat
AZN Share
Trades16,988
AZN
Live RNS
AZN Share
Charts
AZN Level 2
Console
AZN Live
Share Price
AZN Broker
Ratings
AZN Directors
Deals
AZN Financial
Diary
AZN
Fundamentals
AZN Short
Positions
AZN
Media
AZN Company
Research
AZN Company
Timeline
Share Price Information for Astrazeneca (AZN)
Last checked at -
Last checked at 
Intraday Astrazeneca Share Chart
Astrazeneca News
AstraZeneca hails phase 3 trial results of inhibitor Ultomiris
(Alliance News) - AstraZeneca PLC on Saturday announced new data on its kidney disease treatment Ultomiris.
PRESS: AstraZeneca warns it could delay Europe drug launches - FT
(Alliance News) - AstraZeneca PLC could be forced to withhold new medicines from the UK and Europe unless governments pay more for innovative drugs, C...
LONDON MARKET CLOSE: FTSE 100 edges up while US jobs data lifts dollar
(Alliance News) - The FTSE 100 clung on to modest gains on Friday despite weak mining stocks, but Wall Street headed south after stronger-than-expecte...
Worldwide Healthcare Trust outperforms benchmark; praises AstraZeneca
(Alliance News) - Worldwide Healthcare Trust PLC on Friday said pharma company AstraZeneca PLC was its top contributor to its portfolio performance wh...
'It's still working': More are living with cancer as era of targeted drugs takes hold
* Targeted therapies drive rising cancer survival rates, experts say
AstraZeneca breast cancer drug camizestrant shows "sustained" benefit
(Alliance News) - AstraZeneca PLC on Tuesday reported encouraging test results for its breast cancer treatment camizestrant.
BSF Enterprise shares jump on paper in praise of "T-rex leather"
(Alliance News) - BSF Enterprise on Tuesday saw its shares rise after the publication of a paper on one of its subsidiaries' synthetic leather product...
Moderna and other groups get $60 million to develop Ebola vaccine
* CEPI commits just over $60 million to three vaccine groups
Follow the stocks
